Astria Therapeutics (NASDAQ:ATXS) Shares Pass Above Fifty Day Moving Average - Should You Sell?

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) crossed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $5.02 and traded as high as $5.93. Astria Therapeutics shares last traded at $5.81, with a volume of 188,854 shares changing hands.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ATXS. Wedbush reaffirmed an "outperform" rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, June 13th. Six analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $30.00.

Astria Therapeutics Price Performance

The company has a market cap of $327.86 million, a PE ratio of -3.11 and a beta of 0.41. The company has a fifty day moving average price of $5.02 and a 200 day moving average price of $6.14.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). As a group, sell-side analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Deutsche Bank AG grew its holdings in shares of Astria Therapeutics by 54.3% during the fourth quarter. Deutsche Bank AG now owns 39,744 shares of the biotechnology company's stock worth $355,000 after purchasing an additional 13,986 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Astria Therapeutics by 13.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,452 shares of the biotechnology company's stock worth $567,000 after buying an additional 7,756 shares during the last quarter. GAMMA Investing LLC lifted its position in Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company's stock worth $46,000 after buying an additional 7,971 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in Astria Therapeutics in the 4th quarter worth approximately $91,000. Finally, KLP Kapitalforvaltning AS bought a new stake in Astria Therapeutics in the 4th quarter worth approximately $41,000. Hedge funds and other institutional investors own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.